http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Critical Outcome Technologies Reports Fiscal 2017 First Quarter Financial and Operating Results
-
Critical Outcome Appoints Dr. Bharatt Chowrira to Its Board of Directors
-
Critical Outcome Technologies Announces the Opening of Its U.S. Headquarters
-
Critical Outcome Technologies Reports Year-End Financial & Operating Results
-
Critical Outcome Initiates Third Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
-
Critical Outcome Technologies Awards Stock Options
-
Critical Outcome Technologies Appoints Experienced Industry Executive as New President
-
Critical Outcome Announces No Material Change
-
Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study
-
Critical Outcome Technologies Receives $1.6M From Warrant Exercises
-
Critical Outcome to Present at International Li-Fraumeni Syndrome Conference and at BIO International Convention
-
Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment
-
Critical Outcome Technologies Announces Additional Funding Through Warrant Exercises
-
Critical Outcome Technologies Augments Advisory Board Drug Development Experience
-
Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
-
Critical Outcome Technologies Provides Market Update
-
Critical Outcome Technologies Announces Funding Received Through Warrant Exercises
-
Critical Outcome Launches Rosalind -- A Precision Medicine Platform Designed to Provide Cancer Treatment Options
-
Critical Outcome Technologies Reports Fiscal 2016 Third Quarter Financial and Operating Results
-
Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers
-
Critical Outcome Technologies Awards Stock Options
-
Critical Outcome Technologies Reports Second Quarter Financial and Operating Results
-
COTI-2 Moves Into Human Testing
-
Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome
-
Critical Outcome Technologies Awards Stock Options
-
Critical Outcome Technologies Provides Update on Recent Milestone Achievements and Future Strategic Objectives at Annual General Meeting
-
Critical Outcome Technologies Reports First Quarter Financial and Operating Results
-
Critical Outcome Technologies Provides Clarification Regarding Investor Relations Engagement
-
Critical Outcome Technologies Strengthens Its Investor Relations Capabilities
-
Critical Outcome Technologies Reports Year-End Financial and Operating Results
-
Critical Outcome Technologies Completes Private Placement Supporting Its Phase 1 Clinical Trial for p53-Dependent Gynecological Cancers
-
FDA Grants IND to Critical Outcome Technologies for COTI-2, the Company's Activator of Mutant p53 Protein
-
Critical Outcome Technologies Strengthens Its Board
-
Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2
-
Critical Outcome Technologies Files Investigational New Drug Application With the FDA for COTI-2
-
Critical Outcome Technologies Receives First U.S. Patent for Next Generation HIV Treatment
-
Critical Outcome Technologies Inc. Strengthens Its Investor Relations Outreach
-
Critical Outcome Technologies Establishes Advisory Board for the Clinical Development of COTI-2
-
Critical Outcome Technologies Reports Fiscal 2015 Third Quarter Results

